Genor Biopharma Named Jack Hu as Chief Financial Officer and Chief Strategy Officer
6 September 2019 - - Chinese biopharmaceutical company Genor Biopharma has named Jack Hu as Chief Financial Officer and Chief Strategy Officer, the company said.
Before joining Genor, Dr. Hu served as managing director and Head of APAC Healthcare Research at Deutsche Bank, where he covered Asia/China healthcare.
Hu joined Deutsche Bank in 2010 and was ranked No.1 for All-China healthcare research by Institutional Investor magazine from 2015 to 2017.
As a seasoned healthcare professional with deep knowledge of the biotech sector, Dr. Hu has nearly 20 years of experience working in equity research, hedge funds and multinational biopharmaceutical companies.
Hu received a Ph.D. in molecular genetics from the M.D. Anderson Cancer Center and began his career at Wyeth (now part of Pfizer).
He also covered the US biotech sector as a senior biotech analyst with Oppenheimer.
Genor Biopharma is a clinical-stage biopharmaceutical company located in Zhangjiang, Shanghai, China. Genor is focused on the therapeutic areas of oncology and autoimmune diseases. The company delivers a portfolio of novel therapies built to address unmet medical needs.
The company's leading product candidates are late stage innovative monoclonal antibodies. Genor maintains manufacturing facilities with cGMP capabilities in both Shanghai and Yunnan.